Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
60 hedge funds and large institutions have $182M invested in Eidos Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 14 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
93% more capital invested
Capital invested by funds: $94.3M → $182M (+$87.6M)
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
3% more funds holding
Funds holding: 58 → 60 (+2)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.32M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$2.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.83M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.77M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.2M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$2.25M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$1.18M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$766K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$567K |
EIDX Hedge Fund Activity: Q4 2018 in Review
60 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q4 2018, worth a combined $182M — up 93% from $94.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EIDX positions and 14 closed out — a net gain of 3 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $5.32M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.2M sold.
- 60 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q4 2018, up from 58 in Q3 2018.
- Funds reported $182M of Eidos Therapeutics, Inc. Common Stock stock for Q4 2018, up 93% quarter-over-quarter.
- 17 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q4 2018 and 14 closed out, a net change of +3 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q4 2018 was BlackRock, an estimated $5.32M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q4 2018 was Deerfield Management, an estimated $4.2M sold.
Based on aggregated 13F filings for Q4 2018.